George Harrison Talbot

Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA.

Kalidex Pharmaceuticals, Inc. develops antibiotics for the treatment of serious infections. Its lead development candidate KPI-10 is a next-generation fluoroquinolone against a range of important gram-negative and gram-positive pathogens including multi-drug resistant strains and isolates resistant to currently available fluoroquinolones. The company was founded in 2010 by James Ge, Vernocn Jiang and George H. Talbot and is headquartered in Menlo Park, CA.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

The Infectious Diseases Society of America is a non-profit company that provides clinical practice guidelines development and guideline panelists for infectious diseases. The company is based in Arlington, VA and has subsidiaries in the United States. The company specializes in antimicrobial stewardship and have established Antimicrobial Stewardship Centers of Excellence. The CEO of the company is Christopher Busky.

Foundation for the National Institutes of Health, Inc. provides healthcare services. It offers services to public health through scientific discovery, translational research and dissemination of research results through public-private partnerships. The organization was founded in 1996 and is headquartered in Bethesda, MD